The U.S. Food and Drug Administration has approved Edwards Lifesciences' SAPIEN 3 platform, a transcatheter aortic valve ...

The two companies have entered into a strategic partnership to exclusively commercialize Braile’s Transcatheter Aortic Valve Implantation (TAVI) technology across Europe, India, and other ...

1. Current NAV: The Current Net Asset Value of the Axis Ultra Short Duration Fund - Regular Plan as of Apr 17, 2025 is Rs 10.07 for IDCW Daily option of its Regular plan. 2. Returns: Its trailing ...

Adding Farxiga (dapagliflozin) to standard care significantly reduced the risk of death or worsening heart failure in older patients with severe aortic stenosis following transcatheter aortic-valve ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

People with a certain heart valve abnormality are at increased risk ... The researchers are now continuing to study scarring in the heart using MRI (magnetic resonance imaging) and analyse tissue ...

The company is looking to TMTT to support sales growth at a time when the larger transcatheter aortic valve replacement business has slowed. BTIG analysts are predicting TAVR sales will grow 3% in the ...

If you have aortic regurgitation, the flaps around your aortic valve — the valve that pumps blood to your heart — don’t close fully. This causes blood to leak back into your left heart chamber.

For over a decade, the McGill University Health Centre (MUHC) has been at the forefront of aortic valve innovation, advancing how we treat cardiac patients through minimally invasive approaches. That ...

This prospective cohort‐study included adult patients undergoing aortic valve surgery or ascending aortic surgery at a single center (2007–2013). The primary outcome was aortic diameter growth; ...